Novo Nordisk (NVO) is the Danish pharmaceutical company behind Ozempic and Wegovy, two of the most commercially successful drugs ever developed. In 2025, the company generated $47.5 billion in revenue, with a single molecule (semaglutide) responsible for nearly three-quarters of that total. Operating margins run above 40%. Net profit was $15.8 billion. By most financial measures, this is one of the highest-quality pharmaceutical businesses in the world.
The challenge is what comes next. Semaglutide’s US compound patent expires in 2032. Eli Lilly overtook Novo Nordisk in weekly US GLP-1 prescriptions during 2025, and Lilly’s next-generation triple agonist retatrutide just posted 28.7% weight loss in Phase 3, the highest figure ever recorded in a late-stage obesity trial. The IRA’s Medicare drug price negotiations will compress Ozempic and Wegovy pricing starting in 2027. And management just guided for revenue to decline in 2026 for the first time in over a decade. Novo Nordisk is responding with a $25 billion manufacturing buildout, a new CEO, a $5.2 billion acquisition, and a pipeline centered on next-generation obesity drugs. Whether those bets pay off before the patent cliff arrives is the central question for shareholders.
All DKK-to-USD conversions use a rate of 6.50, the approximate exchange rate as of December 31, 2025.
What Novo Nordisk Does
Novo Nordisk operates two business segments: Obesity & Diabetes Care (the vast majority of revenue) and Rare Disease (growth hormones and hemophilia products). The company was formed in 1989 from the merger of two Danish insulin producers dating back to the 1920s.
The Novo Nordisk Foundation, a Danish industrial foundation, controls all A shares, giving it roughly 28% of capital but 78% of voting rights. This structure makes a hostile takeover functionally impossible and gives the Foundation effective control over all major corporate decisions.
Revenue by Product (2025)
| Product | Sales | Category |
|---|---|---|
| Ozempic (semaglutide injection) | $19.6B | Type 2 Diabetes |
| Wegovy (semaglutide injection) | $12.2B | Obesity |
| Rybelsus (oral semaglutide) | $3.4B | Type 2 Diabetes |
| Insulin portfolio (Tresiba, NovoRapid, etc.) | $8.2B | Diabetes |
| Rare Disease (hemophilia, growth disorders) | $3.0B | Rare Disease |
| Saxenda/Victoza (liraglutide, declining) | $1.0B | Obesity/Diabetes |
| Other | $0.3B | — |
| Total | $47.5B |
Semaglutide alone generates over $35 billion in annual sales across Ozempic, Wegovy, and Rybelsus. That makes it the most commercially successful drug molecule in pharmaceutical history. The concentration risk is obvious: three branded formulations of one compound represent nearly three-quarters of the entire company’s revenue.
Geographic Split
The US accounts for roughly 60% of revenue and remains the dominant market. International Operations grew 14% at CER in 2025, led by APAC at 25% growth. China grew just 5%, held back by local competition and pricing dynamics. The US grew 8% at CER but only 3% in reported Danish kroner due to currency headwinds.
The Competitive Landscape
The Approved Market
Eli Lilly’s tirzepatide (Mounjaro for diabetes, Zepbound for obesity) overtook Novo Nordisk in weekly US prescriptions for both obesity and diabetes GLP-1s during 2025. For several years, Novo Nordisk had the GLP-1 market largely to itself with semaglutide. That is no longer the case.
Compounding pharmacies are a persistent competitive and legal headache. Novo Nordisk has filed roughly 130 lawsuits across 40 states against telehealth companies and compounding pharmacies selling unapproved semaglutide products. The highest-profile case, against Hims & Hers, settled in March 2026: Hims agreed to stop advertising compounded GLP-1 drugs and instead sell branded Ozempic and Wegovy through its platform. But compounders are also fighting back. Strive Compounding Pharmacy filed a federal antitrust lawsuit in January 2026 alleging that Novo Nordisk and Eli Lilly unlawfully restricted competition in the GLP-1 market. Despite FDA warning letters and court injunctions, the compounding market remains fragmented and difficult to police. This is unlikely to disappear as a revenue headwind anytime soon.
The IRA adds a structural headwind. Ozempic, Rybelsus, and Wegovy are all included in the second round of Medicare Part D drug price negotiations. Negotiated prices take effect in 2027. Separately, an MFN agreement with the US government for expanded Medicare Part D obesity drug coverage is expected around mid-2026. Both will compress US pricing.
What’s Coming Next
Today’s obesity market is a two-player contest between Novo Nordisk and Eli Lilly. By 2030, it could have five or more companies with approved next-generation drugs. The table below ranks every major investigational or recently approved obesity drug by the weight loss demonstrated so far, including Novo Nordisk’s own pipeline.
| Drug | Company | Best Weight Loss | Stage | Possible Launch | Why It Matters |
|---|---|---|---|---|---|
| Retatrutide | Eli Lilly | 28.7% at 68wk | Phase 3 | 2027-2028 | Highest efficacy ever in a late-stage trial |
| Amycretin | Novo Nordisk | 24.3% at 36wk (no plateau) | Phase 3 started Q1 2026 | 2029-2030 | Single molecule, oral form in development |
| CagriSema | Novo Nordisk | 22.7% at 68wk | NDA filed Dec 2025 | 2027 | FDA decision expected ~Oct 2026 |
| CT-388 | Roche | 22.5% at 48wk | Phase 3 starting | 2029-2030 | Being combined with an amylin drug |
| Tirzepatide (Zepbound) | Eli Lilly | 22.5% at 72wk | Approved | Already on market | Current market leader by Rx volume |
| Semaglutide 7.2mg | Novo Nordisk | 20.7% at 68wk | Submitted to FDA | 2026-2027 | Higher-dose Wegovy |
| MariTide | Amgen | ~20% at 52wk | Phase 3 enrolling | 2028-2029 | Monthly dosing instead of weekly |
| Survodutide | Boehringer Ingelheim | ~19% | Phase 3 | 2028-2029 | Also advancing in MASH |
| Oral semaglutide 25mg | Novo Nordisk | 16.6% | Approved Dec 2025 | Launching now | First oral GLP-1 for obesity |
| VK2735 | Viking Therapeutics | 14.7% at 13wk | Phase 3 | 2028-2029 | Both oral and injectable forms |
| Orforglipron | Eli Lilly | 12.4% at 72wk | Phase 3 | 2027-2028 | Oral pill, no fasting required |
Weight loss figures are not directly comparable across trials due to differences in patient populations, trial duration, and design. But they give a reasonable sense of where each drug sits in the efficacy hierarchy.
Three things stand out from this table.
Lilly has the efficacy lead. Retatrutide’s 28.7% at 68 weeks in Phase 3 tops everything else, including Novo’s entire pipeline. Seven additional Phase 3 readouts are expected through 2026, and Lilly could file for approval by late 2026 or early 2027. If retatrutide is approved and commercially entrenched before Novo’s amycretin even has Phase 3 data (expected 2028), Lilly would own the “most effective” positioning during the critical years when Novo is trying to build its next franchise.
Novo has the broadest portfolio. No other company has four obesity drugs at or near the market simultaneously. CagriSema could be approved by late 2026. Higher-dose Wegovy and oral semaglutide are already submitted or approved. And amycretin’s 24.3% at only 36 weeks with no plateau means its final Phase 3 number could close the gap with retatrutide. If Novo can offer physicians a menu of options (oral pill, standard injection, high-efficacy injection), that breadth matters for market share even if no single product is the most effective.
The oral race is wide open. Lilly’s orforglipron showed lower weight loss than the injectables, but it is a once-daily pill that does not require fasting or water restrictions. Novo’s oral semaglutide 25mg (approved Dec 2025) requires patients to fast overnight and wait 30 minutes before eating. An oral amycretin is also in development. Convenience could matter as much as efficacy for the millions of patients who will never accept a weekly injection.
The Drug Pipeline
Novo Nordisk has seven drugs near FDA submission and a deep bench behind them. Three of those drugs are what matter most for the next five years of revenue: CagriSema (filed for approval), amycretin (entering Phase 3), and efruxifermin (the MASH drug from the Akero acquisition). The rest are either smaller markets, earlier stage, or incremental extensions of existing products.
The pipeline centers overwhelmingly on incretin biology, specifically GLP-1 and amylin receptor agonists targeting obesity and diabetes. The new CEO, Maziar Mike Doustdar (who replaced Lars Fruergaard Jørgensen in August 2025), cut several pipeline programs and laid off roughly 9,000 employees to sharpen this focus.
Near-Term (Submitted or Approved)
| Drug | Indication | Status | Key Data |
|---|---|---|---|
| Oral Semaglutide 25mg | Obesity | FDA approved Dec 2025 | First oral GLP-1 for obesity. 16.6% weight loss |
| Semaglutide 7.2mg (higher-dose Wegovy) | Obesity | Submitted to FDA, positive EMA opinion | 20.7% mean weight loss |
| CagriSema | Obesity | NDA filed to FDA Dec 2025 | 22.7% weight loss in REDEFINE 1 |
| Semaglutide | MASH | Submitted to FDA and EU with priority review | New indication for existing molecule |
| IcoSema (Kyinsu) | Type 2 Diabetes | Approved by EMA, submitted in Japan/China | Semaglutide + weekly insulin combo |
| Icodec (Awiqli) | Type 1 & 2 Diabetes | BLA resubmitted to FDA | Once-weekly basal insulin |
| Denecimig (Mim8) | Hemophilia A | BLA submitted to FDA, MAA to EMA | Monthly injection replacing daily treatments |
CagriSema is the most important near-term launch. It combines two drugs (cagrilintide, an amylin analog, plus semaglutide) into a single weekly injection. The REDEFINE 1 trial showed 22.7% weight loss versus placebo, a meaningful step up from Wegovy’s ~15-17%. The FDA decision is expected around October 2026. The main drawback: because it combines two separate molecules, it is more complex and expensive to manufacture than a single-compound drug.
The Crown Jewel: Amycretin
Amycretin (also called zenagamtide) is a single molecule that mimics both GLP-1 and amylin, the two hormones that make CagriSema work. The difference is that amycretin achieves this in one compound instead of two, which means simpler manufacturing, lower production costs, and the potential for an oral version.
Lancet-published Phase 2 data showed up to 24.3% weight loss at the highest dose at 36 weeks, and 22% at the mid-range dose, with weight loss still declining and no plateau reached. Both subcutaneous and oral formulations are in development. Phase 3 for obesity began in Q1 2026, with a diabetes Phase 3 planned for later in 2026.
This is the single most important pipeline asset for Novo Nordisk’s long-term story. If amycretin delivers Phase 3 data consistent with Phase 2 (expected around 2028-2029), it could become the successor franchise to semaglutide and partially bridge the 2032 patent cliff. The risk is timing: Lilly’s retatrutide already has Phase 3 data showing 28.7% weight loss and could be approved and commercially entrenched by the time amycretin Phase 3 data arrive.
The MASH Bet: Efruxifermin
The $5.2 billion Akero acquisition (closed December 2025) brought efruxifermin into the portfolio. This drug targets MASH, a progressive liver disease affecting tens of millions of people that has no widely approved treatment. Efruxifermin is the only investigational drug to demonstrate reversal of liver fibrosis in cirrhosis patients. Three Phase 3 trials are underway with data expected in 2027-2028. If successful, this could become a meaningful revenue diversifier outside of obesity and diabetes.
Mid-Term (Phase 3)
Beyond the three flagship programs, Novo has several drugs in later-stage development addressing cardiovascular and rare blood diseases:
| Drug | Indication | Key Data |
|---|---|---|
| Cagrilintide monotherapy | Obesity | 11.8% weight loss with lower GI side effects. For patients who cannot tolerate GLP-1 drugs |
| Ziltivekimab | Cardiovascular / CKD | Anti-inflammatory antibody. Phase 3 readouts expected 2026-2027 |
| Coramitug | Heart disease (ATTR cardiomyopathy) | Phase 3 trial initiated |
| Etavopivat | Sickle Cell Disease | Phase 3 trial initiated |
Earlier Stage
Novo has roughly a dozen earlier-stage programs (Phase 1-2) including a GLP-1/GIP/glucagon triple agonist, an oral non-GLP-1 obesity drug (monlunabant), and a glucose-sensitive “smart” insulin. These are 5-10 years from revenue and too early to value, but they represent the company’s long-term optionality beyond amycretin.
What Got Cut
The 2025 restructuring was significant. Novo Nordisk terminated cell therapy R&D entirely, ended a heart failure partnership with Heartseed, discontinued semaglutide for Alzheimer’s (the EVOKE program showed no meaningful benefit in Phase 3), killed three MASH candidates, and dropped early oncology programs. The message from the new CEO is clear: the company is doubling down on obesity, diabetes, and adjacent cardiometabolic conditions, and walking away from therapeutic areas where it lacks competitive advantage.
Financial Profile
Five-Year Income Statement
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $21.7B | $27.2B | $35.7B | $44.7B | $47.5B |
| Gross Profit | $18.0B | $22.8B | $30.2B | $37.8B | $38.5B |
| Gross Margin | 83.2% | 83.9% | 84.6% | 84.7% | 81.0% |
| Operating Profit | $9.0B | $11.5B | $15.8B | $19.7B | $19.6B |
| Operating Margin | 41.7% | 42.3% | 44.2% | 44.2% | 41.3% |
| Net Profit | $7.3B | $8.5B | $12.9B | $15.5B | $15.8B |
| Net Margin | 33.9% | 31.4% | 36.0% | 34.8% | 33.1% |
| EBITDA | $9.9B | $12.6B | $17.2B | $22.7B | $23.0B |
| Diluted EPS (USD) | $1.60 | $1.88 | $2.86 | $3.48 | $3.54 |
Revenue grew from $22 billion to $48 billion in four years. But 2025 marked an inflection point. Operating profit declined for the first time, falling 0.5% year over year. Gross margin dropped 370 basis points to 81%, driven by Catalent manufacturing site integration costs, roughly $1.2 billion in one-off restructuring charges from the 9,000-employee layoff, and ongoing capacity expansion expenses. Excluding restructuring, operating profit grew about 6% as reported and 13% at CER.
The Capex Commitment
This is where the financial story gets unusual for a pharmaceutical company. Novo Nordisk spent $9.3 billion on PP&E capex in 2025, up from $7.3 billion in 2024 and $4.0 billion in 2023. That is 19.4% of revenue going to capital expenditure, a level more typical of a semiconductor manufacturer than a pharma company.
The buildout spans multiple continents:
| Facility | Total Budget | Spent | Expected Operational |
|---|---|---|---|
| Kalundborg API (Denmark) | $3.4B | $3.1B | 2027 |
| Kalundborg API expansion | $7.6B | $3.6B | 2029 |
| Clayton, NC (USA) | $4.2B | $2.1B | 2029 |
| Chartres (France) | $2.6B | $1.0B | 2026-2028 |
| Hillerød API (Denmark) | $2.4B | $1.6B | 2028 |
| Other (4 facilities) | $4.3B | $2.8B | Various |
| Total | ~$25B | ~$14B |
Management is betting that GLP-1 demand will continue growing for years. If they are right, this manufacturing capacity becomes a competitive moat that smaller competitors cannot easily replicate. If demand plateaus or competitors erode share faster than expected, a significant portion of this spending becomes sunk cost.
Balance Sheet
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | — | $71.6B | $83.5B |
| Total Equity | — | $22.1B | $29.8B |
| Net Debt | $1.4B | $10.7B | $14.7B |
| Eurobonds Outstanding | — | — | ~$17.5B (EUR 16.3B) |
The balance sheet transformation has been rapid. Novo Nordisk went from near net-cash in 2023 to $14.7 billion in net debt by end of 2025. The drivers: the Catalent acquisition in 2024, the $5.2 billion Akero acquisition in 2025, and $9.3 billion in capex. The company issued roughly $10.8 billion in new Eurobonds during 2025 alone to fund all of this.
Cash Flow and Capital Allocation
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Free Cash Flow | $8.8B | $10.5B | ($2.3B) | $4.4B |
| Dividends | $4.3B | $6.5B | $7.8B | $8.0B |
| Share Buybacks | $3.7B | $4.6B | $3.1B | $0.2B |
Share buybacks collapsed from $3-5 billion per year to essentially zero in 2025. All available cash is being funneled into the manufacturing buildout and acquisitions. Management announced a $2.3 billion buyback program for 2026, but even that is modest relative to the company’s size.
2026 Guidance
Management guided for adjusted sales growth of -5% to -13% at CER for 2026. On a non-adjusted basis, the midpoint implies roughly a 1% decline. The drivers are the MFN pricing agreement for expanded Medicare obesity coverage, loss of some international semaglutide patents, and intensifying competition. This is the first guided revenue decline in over a decade.
The Patent Cliff
Semaglutide’s US compound patent expires in 2032. Multiple generic manufacturers have filed ANDAs for Ozempic, Wegovy, and Rybelsus. Novo Nordisk has settled with several of these filers on confidential terms and has additional formulation, device, and method-of-use patents that could extend effective exclusivity on specific products beyond 2032.
How much of semaglutide’s revenue survives the patent cliff depends on several factors: how quickly generics enter (biologics are harder to copy than small molecules, but semaglutide is a relatively simple peptide), whether device and formulation patents hold up, and how far along next-generation products like amycretin are in replacing semaglutide volumes. In the base case, expect meaningful revenue erosion starting in 2032-2033, partially offset by pipeline products that should be on the market by then.
Valuation
DCF Model
The DCF projects ten years of unlevered free cash flow (2026-2035) with a Gordon Growth terminal value.
Key assumptions:
- Revenue declines 3% in 2026 (consistent with guidance), recovers through 2028-2031 as CagriSema and amycretin launch, then contracts in 2032-2033 as semaglutide generics arrive
- Operating margins range from 37% (trough during generic erosion) to 44% (peak during pipeline ramp)
- Capex normalizes from 18% of revenue in 2026 to 8% by 2032 as the factory buildout completes
- WACC of 9.5% (higher than typical large-cap pharma to reflect patent concentration risk, competitive intensity, and currency exposure)
- Terminal growth of 2.5%
- Long-term tax rate of 22%
Projected Financials
| Year | Revenue | Growth | Op Margin | EBITDA | Capex | Unlevered FCF |
|---|---|---|---|---|---|---|
| 2026 | $46.1B | -3.0% | 42.0% | $22.6B | $8.3B | $10.1B |
| 2027 | $48.4B | 5.0% | 43.0% | $24.2B | $7.8B | $11.8B |
| 2028 | $53.3B | 10.0% | 44.0% | $27.2B | $7.5B | $14.3B |
| 2029 | $59.7B | 12.0% | 44.0% | $30.4B | $7.2B | $17.2B |
| 2030 | $65.6B | 10.0% | 44.0% | $33.5B | $6.6B | $20.3B |
| 2031 | $70.9B | 8.0% | 43.0% | $35.1B | $6.4B | $21.7B |
| 2032 | $73.0B | 3.0% | 40.0% | $33.9B | $5.8B | $21.6B |
| 2033 | $69.4B | -5.0% | 37.0% | $30.2B | $5.6B | $19.2B |
| 2034 | $67.9B | -2.0% | 38.0% | $30.2B | $5.4B | $19.2B |
| 2035 | $70.0B | 3.0% | 39.0% | $31.8B | $5.6B | $20.1B |
Valuation Summary
| Component | Value |
|---|---|
| PV of Free Cash Flows (2026-2035) | $104.7B |
| PV of Terminal Value | $119.0B |
| Enterprise Value | $223.7B |
| Less: Net Debt | $14.7B |
| Equity Value | $209.0B |
| Shares Outstanding | 4,465M |
| Value per ADR | $47 |
Terminal value accounts for 53% of enterprise value. That is within the normal range for a DCF but worth flagging: more than half of the implied value depends on what happens after 2035.
Implied Multiples
| Multiple | Implied | Large-Cap Pharma Range |
|---|---|---|
| EV/Revenue (2025) | 4.7x | 4-8x |
| EV/EBITDA (2025) | 9.7x | 12-18x |
| P/E (2025) | 13.3x | 15-25x |
The implied multiples land at the low end of pharma ranges and below them on EV/EBITDA and P/E. This reflects the patent cliff drag on the terminal value, near-term FCF depression from elevated capex, and increasing competitive risk from Lilly, Roche, and Amgen. A company growing revenue 10% with 44% operating margins would normally command higher multiples. The 2032 overhang and competitive pipeline are doing real work in the model.
Scenario Analysis
| Scenario | Assumptions | Value per ADR |
|---|---|---|
| Bear | Revenue 3% lower each year, margins 3% worse, 11% WACC, 2% terminal growth | $26 |
| Base | As modeled | $47 |
| Bull | Revenue 3% higher each year, margins 2% better, 8.5% WACC, 3% terminal growth | $79 |
Bear case ($26): Amycretin disappoints in Phase 3 or faces safety issues. Retatrutide launches first and captures the premium efficacy tier. Lilly’s tirzepatide and orforglipron dominate both injectable and oral markets. IRA and MFN pricing destroy US margins. Compounding pharmacies continue to erode volume. Semaglutide generics arrive on schedule in 2032 with no meaningful patent extension. The $25 billion in manufacturing capex becomes partially stranded.
Base case ($47): CagriSema and amycretin both succeed commercially. Amycretin carves out a differentiated position (simpler manufacturing, oral option, favorable tolerability) even if retatrutide leads on headline efficacy. The patent cliff is real but manageable because amycretin is on the market by 2030 and ramping. International growth partially offsets US pricing pressure. Capex normalizes after 2029 and the manufacturing base becomes a competitive advantage.
Bull case ($79): Amycretin replicates or exceeds its Phase 2 data (up to 24% weight loss, not plateaued) and becomes a mega-blockbuster exceeding $20 billion in peak sales. Efruxifermin succeeds in MASH and adds $5 billion or more in diversified revenue. The obesity TAM expands as global coverage broadens and earlier intervention becomes standard of care. Formulation patents on semaglutide products extend effective exclusivity beyond 2032. Retatrutide faces tolerability issues at high doses that limit its commercial positioning.
Sensitivity Table (USD per ADR)
| WACC / Terminal Growth | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 8.0% | $55 | $57 | $61 | $65 | $70 |
| 8.5% | $50 | $53 | $55 | $59 | $63 |
| 9.0% | $47 | $49 | $51 | $53 | $57 |
| 9.5% | $43 | $45 | $47 | $49 | $52 |
| 10.0% | $40 | $42 | $43 | $45 | $47 |
| 10.5% | $38 | $39 | $40 | $42 | $44 |
| 11.0% | $35 | $37 | $38 | $39 | $40 |
Even at the most generous end of the sensitivity table (8% WACC, 3.5% terminal growth), the model only reaches $70 per ADR. The range across reasonable assumptions is roughly $35-$63.
What Could Make This Valuation Wrong
The biggest source of potential error is the 2029-2035 revenue trajectory. If amycretin turns out to be a $30 billion drug by 2034, the post-patent-cliff revenue decline would be far shallower than modeled, and the terminal value would be significantly higher. Conversely, if both CagriSema and amycretin face clinical setbacks, the patent cliff becomes an earnings cliff with nothing to break the fall.
Competitive intensity is the second-largest risk factor. The base case assumes Novo Nordisk can sustain 8-12% revenue growth through 2031 while Lilly, Roche, Amgen, and smaller players are all launching competing drugs. If the obesity market fragments more than expected, Novo’s pipeline products may generate lower peak sales than modeled, even if they succeed clinically.
The WACC assumption also matters. At 9.5%, the model prices in more risk than the market typically assigns to a company of this size and profitability. If the Foundation ownership structure and the obesity megatrend reduce business risk, 8.5-9.0% is defensible, which pushes the value into the $51-$55 range.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| CagriSema FDA review | First next-gen GLP-1 approval for Novo. Sets trajectory for 2027+ revenue | PDUFA ~Oct 2026 |
| Retatrutide TRIUMPH Phase 3 readouts | Seven readouts in 2026 including obesity, T2D, MASH, heart failure. Determines how strong Lilly’s next-gen threat is | Throughout 2026 |
| Orforglipron NDA filing | If Lilly files in late 2026, it could be approved in 2027 as a competing oral obesity pill | Late 2026 |
| Amycretin Phase 3 interim data | The single most important Novo pipeline readout. Confirms or refutes 24%+ weight loss | 2028 |
| MFN pricing agreement details | Determines magnitude of US price cuts for expanded Medicare obesity coverage | Mid-2026 |
| IRA negotiated prices for Ozempic/Wegovy/Rybelsus | Direct revenue impact starting 2027. Amount of price reduction will be material | Late 2026 announcement |
| Efruxifermin Phase 3 MASH data | $5.2B acquisition thesis depends on this | 2027-2028 |
| Icodec (Awiqli) FDA resubmission outcome | Once-weekly insulin for US market | 2026 |
| Quarterly GLP-1 prescription data (IQVIA) | Tracks competitive dynamics vs Lilly’s tirzepatide in real time | Ongoing |
| Semaglutide ANDA litigation outcomes | Could accelerate or delay generic entry around 2032 | Ongoing |
Sources:
- 20-F filed February 4, 2026
- Annual Report 2025: Financial Performance
- Annual Report 2025: Innovation and Therapeutic Focus
- Annual Report 2025: Five-Year Overview
- Lancet Phase 1b/2a amycretin obesity data (2025)
- Lilly TRIUMPH-4 retatrutide Phase 3 topline results (Dec 2025)
- Roche CT-388 Phase 2 results (Jan 2026)
- Amgen MariTide Phase 2 results (NEJM, June 2025)
- Viking Therapeutics VK2735 Phase 2 oral results (Aug 2025)
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.